obinutuzumab beta

Obinutuzumab beta is a glycoengineered, Type II, humanized anti-CD20 monoclonal antibody. It is a specific designation used in clinical trials, notably those sponsored by the Chinese PLA General Hospital, to evaluate the drug's efficacy in treating autoimmune conditions such as ANCA-associated glomerulonephritis (AAGN) and ANCA-associated vasculitis. As a Type II anti-CD20 antibody, it is designed to induce direct cell death and enhanced antibody-dependent cellular cytotoxicity (ADCC) with minimal complement-dependent cytotoxicity (CDC), distinguishing it from Type I antibodies like rituximab. The drug works by targeting the CD20 antigen on B cells, leading to their depletion and thereby reducing the production of pathogenic autoantibodies. In clinical studies for AAGN, it is often investigated in combination with rapid-tapering or low-dose glucocorticoid regimens to improve patient outcomes while minimizing steroid-related toxicity.

Other names

奥妥珠单抗βobinutuzumab